81.80
+1.87%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syngen Biotech Co
Its shares trade on Taipei Exchange under the ticker 8279.TWO. It has been listed since 14 November 2014. In the fiscal year to 31 December 2025, it reported revenue of TWD 2.14bn and net income of TWD 271.6m. At that date it held total assets of TWD 3.05bn and shareholders' equity of TWD 2.37bn.
Syngen Biotech Co., Ltd. engages in the manufacture and sale of microbial pharmaceutical and Biochemical Nutrition. The company is headquartered in Tainan, Tainan. The company went IPO on 2014-11-14. The Company’s products mainly consist of active pharmaceutical ingredients, health food raw materials, medical equipment, such as bone density analyzers, blood glucose analyzers and biochemical analyzers, as well as animal health products and others. The firm distributes its products mainly in Taiwan, Iran, South Korea and Egypt.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Nov 2014
- Website
- syngen.com.tw ↗
Leadership
Pay as last reported
- Mr. Wei-Jen ChenChairman of the Board, General Manager, since 2005
- Ms. Zihui WangFinance Manager, Corporate Governance Officer
- Mr. Tzu-Ting FanDirector
- Cuiwen YeDirector
- Ms. Zhaoyuan HuangIndependent Director
- Mr. Shijie LiIndependent Director
- Mr. Aqing TuIndependent Director
- Mr. Shengshi WangIndependent Director
- Mr. Jiezun WuSpecial Assistant to General Manager's Office, since 2014
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Syngen Biotech Co Ltd manufactures active pharmaceutical ingredients and health food raw materials.
- The company distributes its products in Taiwan, Iran, South Korea, and Egypt.
- Syngen Biotech Co Ltd is headquartered in Tainan, Tainan.
Weaknesses
- Syngen Biotech Co Ltd went public in November 2014, indicating a relatively recent listing history.
- The firm's product portfolio includes medical equipment such as bone density analyzers and blood glucose analyzers.
- The company operates primarily within the Health Care sector in Taiwan.
Opportunities
- Syngen Biotech Co Ltd can expand its distribution of animal health products to new international markets.
- The company may leverage its manufacturing capabilities for biochemical nutrition to enter emerging economies.
- Syngen Biotech Co Ltd can grow its presence in Egypt and Iran through its existing distribution network.
Threats
- Syngen Biotech Co Ltd faces competition in the pharmaceutical industry from other manufacturers of active ingredients.
- Regulatory changes in Taiwan could impact the manufacturing and sale of medical equipment like biochemical analyzers.
- Geopolitical instability in distribution countries such as Iran and Egypt may disrupt Syngen Biotech Co Ltd's sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.